AR072639A1 - Pirazinonas como moduladores de la actividad del receptor del factor liberador de corticotropina - Google Patents
Pirazinonas como moduladores de la actividad del receptor del factor liberador de corticotropinaInfo
- Publication number
- AR072639A1 AR072639A1 ARP090102928A ARP090102928A AR072639A1 AR 072639 A1 AR072639 A1 AR 072639A1 AR P090102928 A ARP090102928 A AR P090102928A AR P090102928 A ARP090102928 A AR P090102928A AR 072639 A1 AR072639 A1 AR 072639A1
- Authority
- AR
- Argentina
- Prior art keywords
- pirazinonas
- modulators
- compound
- releasing factor
- receiver activity
- Prior art date
Links
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 title 1
- 239000003488 releasing hormone Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- PJMUNXORSUNUCV-OAHLLOKOSA-N 4-[(1s)-1-cyclopropyl-2-methoxyethyl]-6-[[6-(difluoromethoxy)-2,5-dimethylpyridin-3-yl]amino]-5-oxopyrazine-2-carbonitrile Chemical compound C1([C@@H](COC)N2C(C(NC=3C(=NC(OC(F)F)=C(C)C=3)C)=NC(=C2)C#N)=O)CC1 PJMUNXORSUNUCV-OAHLLOKOSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 208000029650 alcohol withdrawal Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8523008P | 2008-07-31 | 2008-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072639A1 true AR072639A1 (es) | 2010-09-08 |
Family
ID=40651774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102928A AR072639A1 (es) | 2008-07-31 | 2009-07-30 | Pirazinonas como moduladores de la actividad del receptor del factor liberador de corticotropina |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7932256B2 (https=) |
| EP (1) | EP2303867B1 (https=) |
| JP (1) | JP5396474B2 (https=) |
| KR (1) | KR20110040870A (https=) |
| CN (1) | CN102171205B (https=) |
| AR (1) | AR072639A1 (https=) |
| AU (1) | AU2009277057A1 (https=) |
| MX (1) | MX2011000754A (https=) |
| TW (1) | TW201008926A (https=) |
| WO (1) | WO2010014280A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US10077443B2 (en) | 2012-11-15 | 2018-09-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
| CN104955952A (zh) | 2013-01-30 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | Lna寡核苷酸碳水化合物缀合物 |
| WO2015112642A1 (en) | 2014-01-21 | 2015-07-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
| CA3121920A1 (en) | 2018-12-07 | 2020-06-11 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| IT201900021216A1 (it) | 2019-11-14 | 2021-05-14 | Isagro Spa | Processo per la preparazione di derivati piridinici e corrispondenti piridil-formammidine |
| CN112552184B (zh) * | 2020-12-18 | 2022-05-10 | 诚达药业股份有限公司 | 一种含环丙基手性胺盐酸盐的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159980A (en) * | 1996-09-16 | 2000-12-12 | Dupont Pharmaceuticals Company | Pyrazinones and triazinones and their derivatives thereof |
| CN1231473C (zh) * | 2000-02-16 | 2005-12-14 | 神经能质公司 | 取代的芳基吡嗪 |
| RU2003136151A (ru) * | 2001-06-12 | 2005-05-20 | Ньюроджин Корпорейшн (US) | 2, 5-диарилпиразины, 2, 5-диарилпиридины и 2, 5-диарилпиримидины в качестве модуляторов рецептора кортикотропин-рилизинг-фактора 1 (крф1) |
| WO2004046136A1 (en) | 2002-11-21 | 2004-06-03 | Pharmacia & Upjohn Company Llc | Pyrazine compounds as crf modulators |
-
2009
- 2009-04-24 US US12/429,810 patent/US7932256B2/en active Active
- 2009-04-27 EP EP09789614.6A patent/EP2303867B1/en not_active Not-in-force
- 2009-04-27 CN CN2009801386016A patent/CN102171205B/zh not_active Expired - Fee Related
- 2009-04-27 JP JP2011521135A patent/JP5396474B2/ja not_active Expired - Fee Related
- 2009-04-27 AU AU2009277057A patent/AU2009277057A1/en not_active Abandoned
- 2009-04-27 KR KR1020117002253A patent/KR20110040870A/ko not_active Withdrawn
- 2009-04-27 WO PCT/US2009/041793 patent/WO2010014280A1/en not_active Ceased
- 2009-04-27 MX MX2011000754A patent/MX2011000754A/es active IP Right Grant
- 2009-07-22 TW TW098124751A patent/TW201008926A/zh unknown
- 2009-07-30 AR ARP090102928A patent/AR072639A1/es not_active Application Discontinuation
-
2011
- 2011-03-21 US US13/052,458 patent/US8372847B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US7932256B2 (en) | 2011-04-26 |
| CN102171205A (zh) | 2011-08-31 |
| CN102171205B (zh) | 2013-08-07 |
| JP5396474B2 (ja) | 2014-01-22 |
| US20110166160A1 (en) | 2011-07-07 |
| TW201008926A (en) | 2010-03-01 |
| KR20110040870A (ko) | 2011-04-20 |
| AU2009277057A1 (en) | 2010-02-04 |
| MX2011000754A (es) | 2011-02-24 |
| EP2303867B1 (en) | 2014-12-17 |
| WO2010014280A1 (en) | 2010-02-04 |
| EP2303867A1 (en) | 2011-04-06 |
| US20100029684A1 (en) | 2010-02-04 |
| US8372847B2 (en) | 2013-02-12 |
| JP2011529886A (ja) | 2011-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072639A1 (es) | Pirazinonas como moduladores de la actividad del receptor del factor liberador de corticotropina | |
| UY32968A (es) | Compuestos heterocíclicos fusionados como moduladores del receptor de orexina | |
| MX382599B (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina. | |
| DOP2013000267A (es) | Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3 | |
| UY30253A1 (es) | Benzoimidazol -2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina | |
| CL2011001263A1 (es) | Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma. | |
| MX2010003117A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| ME01532B (me) | Jedinjenja | |
| MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
| CL2008003787A1 (es) | Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras. | |
| MX363118B (es) | Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). | |
| BRPI0910368B8 (pt) | uso de um ou mais biointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores | |
| CR20120273A (es) | OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO MODULADORES DEL RECEPTOR DE OREXINA | |
| UY30917A1 (es) | Moduladores 2-aminopiridina del receptor histamina h | |
| CL2009000990A1 (es) | Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras. | |
| MX2010013726A (es) | Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina. | |
| IN2012DN02469A (https=) | ||
| CU20090148A7 (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso | |
| BR112015010663A8 (pt) | formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo | |
| SV2010003662A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081 | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| MX2007009162A (es) | Formas de dosis rsistente al alcohol. | |
| DOP2012000063A (es) | (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer | |
| CL2012000702A1 (es) | Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson. | |
| IN2012DN02471A (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |